Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia (RIVAL-PAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02260622|
Recruitment Status : Completed
First Posted : October 9, 2014
Last Update Posted : July 22, 2019
Background: Up to 10% of patients with peripheral arterial disease (PAD) will develop critical limb ischemia (CLI) which is a decrease of blood flow in the arteries of the limb. CLI results in resting pain, ulcers, gangrene, and limb loss. The outcome for patients with CLI is poor. Within 3 months of onset, 12% of patients will require an amputation (removal of part of the limb) and 9% will die of major cardiovascular events (heart attack or stroke). Percutaneous angioplasty (PTA), a procedure used to open the blockages in blood flow, has become the first-line treatment for CLI given its effectiveness, lower cost, and lower risk of complications. However, 40% of patients will have re-narrowing of the arteries (restenosis) following the PTA procedure. This is thought to happen in part due to build up of blood cells called platelets which can also lead to the formation of blood clots. In order to try to avoid this problem, most patients are prescribed a combination of two blood thinning medications, acetylsalicylic acid (ASA or aspirin) and clopidogrel (the brand name is Plavix).
The purpose of this study is to determine if a new blood thinner called rivaroxaban, given in combination with aspirin, would be more effective in preventing re-narrowing of the arteries than the current standard of care (aspirin and clopidogrel).
Rivaroxaban is a pill and does not require blood test monitoring. It has been approved by Health Canada for use in prevention of blood clots in patients undergoing hip or knee surgery and to treat patients with blood clots in their legs and lungs. Low dose aspirin has been approved for reducing the risk of heart attacks and strokes. These medications have not been tested together in patients for prevention of re-narrowing of their arteries
This is a pilot study conducted at one center, The Ottawa Hospital.
It is a Phase 2 open label randomized controlled trial.
Following the PTA procedure, once all inclusion/exclusion criteria are met, the participant will be randomized into one of two groups:
- Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily OR
- Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
Visits will occur at 7 days, 30 days, 90 days, 6 months and 12 months. Participants will be followed for 12 months (± 14 days) in total. All adverse events will be collected for the duration of the study.
|Condition or disease||Intervention/treatment||Phase|
|Critical Limb Ischemia||Drug: rivaroxaban plus aspirin Drug: clopidogrel plus aspirin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia|
|Study Start Date :||October 2014|
|Actual Primary Completion Date :||June 2017|
|Actual Study Completion Date :||March 2019|
Active Comparator: clopidogrel plus aspirin
Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
Drug: clopidogrel plus aspirin
Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
Experimental: rivaroxaban plus aspirin
Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
Drug: rivaroxaban plus aspirin
Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
Other Name: treatment arm
- RAS [ Time Frame: 1 year ]The primary outcome is a combined endpoint consisting of any Reintervention, Above ankle amputation and restenosis (RAS) at one year
- Improved Rutherford Scale [ Time Frame: 1 year ]Clinical improvement defined as cumulative improvement of 2 classes of the Rutherford scale without the need for repeated TLR in surviving patients.
- Event-free survival [ Time Frame: 1 year ]Event-free survival
- Overall survival [ Time Frame: 1 year ]Overall survival
- TLR [ Time Frame: 1 year ]Target lesion revascularization (TLR) between day 1 and final visit
- TVR [ Time Frame: 1 year ]Target vessel revascularization (TVR between day 1 and final visit)
- Peri-procedure death [ Time Frame: 30 days ]Peri-procedure death within 30 days
- MACE [ Time Frame: 1 year ]Cumulative rate of major adverse cardiovascular events between day 1 and final visit
- Major Bleeding [ Time Frame: 90 days ]Cumulative rate of major bleeding between day 1 and day 90
- Minor Bleeding [ Time Frame: 90 days ]Cumulative clinically relevant or minor bleeding between day 1 and day 90
- Biomarkers [ Time Frame: 90 days ]Biological plausibility by measuring coagulation changes and SMC proliferation markers within 7 and 90 days based on the following markers: D-dimer, soluble CD40/44 ligands, and ERK 1/2
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02260622
|The Ottawa Hospital|
|Ottawa, Ontario, Canada, K1Y4E9|
|Principal Investigator:||Esteban Gandara, MD||Ottawa Hospital Research Institute|
|Principal Investigator:||Prasad Jetty, MD||Ottawa Hospital Research Institute|